NMN Stability in Supplements: ICH-Aligned Testing Protocol and Formulation Best Practices

Why NMN Stability Is a Critical Formulation Concern

NMN (β-Nicotinamide Mononucleotide) is hygroscopic, thermolabile, and photosensitive. These properties make bulk ingredient stability testing — and formulation stability testing — essential steps before launch. Formulators who skip these steps risk launching products that lose significant potency before their stated shelf life, or fail regulatory stability testing post-launch.

Degradation Pathways

NMN degrades primarily through:

• Hydrolysis: NMN can hydrolyze to nicotinamide mononucleotide base components under aqueous conditions, especially above pH 6. This is the primary degradation route in liquid formulations.
• Oxidation: The nicotinamide ring is susceptible to oxidative degradation, producing nicotinamide N-oxide and related impurities.
• Epimerization: Under acidic conditions (pH < 4), the ribose portion can epimerize, reducing the proportion of the β-isomer. This is rarely seen at typical supplement conditions.
• Moisture-induced condensation: In powder forms, high moisture promotes degradation via Maillard-like reactions with reducing sugars if present.

ICH-Aligned Stability Testing Protocol

Following ICH Q1A(R2) guidelines, a standard stability protocol for NMN bulk ingredient should include:

Key Analytical Tests at Each Timepoint

• Assay (HPLC): Primary purity, target ≥98.0% throughout shelf life. Flag any decrease > 1% from initial.
• Water content (Karl Fischer): Must remain ≤ 1.5% (pharmaceutical grade). Spike in moisture often precedes potency loss.
• Specific rotation: Monitor for epimerization. Alert if [α]D²⁵ falls below +38°.
• Impurity profile (HPLC): Track individual impurities — any single impurity exceeding 0.15% (ICH Q3B threshold for new degradants) requires identification.
• Appearance: Color change from white to yellow indicates oxidative degradation. Caking indicates moisture ingress.
• pH (for liquid forms): Maintain between 4.5–6.0 to minimize hydrolysis.

Formulation-Specific Stability Considerations

Capsule: Most stable format for NMN. Use HDPE bottles with desiccant (2g silica per 60-count bottle) or blister packs with aluminum foil backing. Avoid clear PET containers — UV exposure accelerates degradation.

Tablet: NMN is compatible with common tableting excipients (MCC, HPMC, stearic acid). Avoid calcium phosphate dibasic — its alkaline pH promotes hydrolysis. Film coating with HPMC provides a moisture barrier.

Powder sachet: High surface area increases exposure. Use triple-layer aluminum foil sachets (PET/AL/PE). Nitrogen flush before sealing. Shelf life typically 12–18 months vs. 24 months for capsules.

Liquid (beverage or IV): Most challenging. Buffer to pH 4.5–5.0 (citrate or acetate buffer). Sterilize by sterile filtration (0.22 μm) not terminal heat. Nitrogen headspace essential. Consider lyophilized powder for injection (pharma-grade applications).

Packaging Recommendations

• Bulk storage: double HDPE liner, foil-laminated aluminum drums, nitrogen purge, silica desiccant.
• Consumer packaging: HDPE or glass amber bottle, induction seal, oxygen absorber.
• Transport: avoid direct sunlight; cold chain (2–8°C) for pharmaceutical grade; ambient with desiccant for supplement grade.

PathGene Stability Documentation

PathGene NMN has passed 24-month real-time stability testing (25°C/60% RH) with assay ≥99.0% at all timepoints. Full stability study data available upon request under NDA. Request NMN stability data package.